Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit

A recent G-BA decision provides a systematic evaluation of Glofitamab Gemcitabine DLBCL, combined with Gemcitabine and Oxaliplatin (GemOx), for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. The review, conducted under Germany’s early benefit assessment process (§ 35a SGB V), concludes that due to the absence of suitable comparative data, no additional benefit of the Glofitamab regimen over standard therapies has been demonstrated. As a result, Glofitamab plus GemOx cannot be considered superior to existing alternatives for this indication.

Insufficient Comparative Data

Underlying the assessment is the critical observation that no randomized controlled trials (RCTs) comparing Glofitamab plus GemOx to the current standard of care—either Tafasitamab with Lenalidomide or Polatuzumab Vedotin with Bendamustine and Rituximab—were available. The pivotal STARGLO trial (GO41944) compared Glofitamab plus GemOx with Rituximab plus GemOx, a regimen not aligned with the updated standard comparators determined by the Gemeinsamer Bundesausschuss (G-BA). Despite data for Glofitamab versus Rituximab-based therapy, the lack of direct comparison to recommended references as per the May 2025 guidance meant that patient-relevant outcomes could not be meaningfully attributed against current best practice. This led IQWiG—the German Institute for Quality and Efficiency in Health Care—to state unequivocally that a clinical added benefit is “not proven” under the defined criteria.

Furthermore, the pharmaceutical company’s alternative analyses could not compensate for the fundamental absence of direct or even indirect comparative data with the appropriate reference therapies. The granularity of the target population—adults with DLBCL NOS, relapsed/refractory, and ineligible for stem cell transplantation—aligns well with clinical practice. Yet the assessment’s rigor reflects the high standards set for reimbursement and market access in the German AMNOG context.

Adhering to Global Standards

The rigorous approach adopted by IQWiG and the G-BA parallels evolving health technology assessment (HTA) practices globally. Robust RCT evidence is a principal demand of agencies like the UK’s National Institute for Health and Care Excellence (NICE) and France’s Haute Autorité de Santé (HAS) for similar evaluations. With rapidly expanding therapeutic options for DLBCL—notably with the rise of CAR-T cell therapies and bispecific antibodies—complexity in treatment algorithms has increased. Regulatory and payer expectations for direct comparative evidence have grown in tandem.

Consequences for Market Dynamics

This finding carries substantial implications for health economics and outcomes research (HEOR), pricing, and reimbursement:

First, without evidence of added clinical benefit over standard therapies, Glofitamab plus GemOx will be assigned to the lowest rebate or reference price category in the German system. Market access is thus intricately tied to comparative clinical value as established through the early benefit assessment pipeline.

Second, for policy-makers and payers, the report signals the need for strategic alignment in clinical trial design. The absence of relevant comparator studies can stall access to innovation despite regulatory approval—a phenomenon increasingly reported in real-world access delays for novel therapies in DLBCL across Europe.

Third, the assessment highlights a persistent methodological and policy challenge for industry and HTA bodies. As novel agents proliferate, the complexity of defining “purposeful” comparators and identifying appropriate patient segments intensifies.

Looking ahead, manufacturers will need to ensure the availability of high-quality, appropriately designed comparative studies to support meaningful demonstration of additional benefit for innovative therapies. Otherwise, novel treatments risk minimal uptake due to restrictive reimbursement outcomes—even in the face of substantial scientific promise and unmet clinical need.

In summary, the report on Glofitamab Gemcitabine DLBCL underscores the primacy of comparative effectiveness evidence in achieving favorable market access, pricing, and reimbursement outcomes in Germany’s highly structured HTA environment. It exemplifies ongoing dynamics in oncology HEOR, where methodological rigor, evolving clinical paradigms, and the economic stakes of novel therapeutics are tightly interwoven.